Cyclo Therapeutics, Inc. Warrant
CYTHW
CYTHW was delisted on the 25th of March, 2025.
4 hedge funds and large institutions have $188K invested in Cyclo Therapeutics, Inc. Warrant in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
40% less capital invested
Capital invested by funds: $315K → $188K (-$127K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
-$3.51K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$586 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WVP
1
Worth Venture Partners
Fort Lee,
New Jersey
| $99K | – | – | – |
|
|
EAM
2
Empery Asset Management
New York
| $87K | -$3.51K | -1,964 | -3% |
|
|
3
UBS Group
Zurich,
Switzerland
| $2K | -$586 | -328 | -22% |
|
CYTHW Hedge Fund Activity: Q1 2022 in Review
4 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Cyclo Therapeutics, Inc. Warrant (CYTHW) for Q1 2022, worth a combined $188K — down 40% from $315K a quarter earlier.
Fund positioning in CYTHW was balanced in Q1 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.
The largest seller was Empery Asset Management, cutting an estimated $3.51K.
- 4 institutional investors held Cyclo Therapeutics, Inc. Warrant (CYTHW) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $188K of Cyclo Therapeutics, Inc. Warrant stock for Q1 2022, down 40% quarter-over-quarter.
- 0 funds opened new Cyclo Therapeutics, Inc. Warrant positions in Q1 2022 and 0 closed out.
- The largest Cyclo Therapeutics, Inc. Warrant seller in Q1 2022 was Empery Asset Management, an estimated $3.51K sold.
Based on aggregated 13F filings for Q1 2022.